Browse more Reports on Women's Health Therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceutica...
This report provides comprehensive information on the therapeutic development
for Polycystic Ovarian Syndrome, complete wi...
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Polycystic Ovarian Syndrome - Pipeline R...
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Scope For Polycystic Ovarian Syndrome - ...
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Reasons to Buy:
• Provides strategically...
For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441
RnRMarkertResearch
RnRMarketResear...
of 6

Polycystic Ovarian Syndrome Pipeline Therapeutics Development Review H2 2015

This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects
Published on: Mar 4, 2016
Published in: Healthcare      
Source: www.slideshare.net


Transcripts - Polycystic Ovarian Syndrome Pipeline Therapeutics Development Review H2 2015

  • 1. Browse more Reports on Women's Health Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health- therapeutics . Polycystic Ovarian Syndrome - Pipeline Review, H2 2015 By RnRMarketResearch.com © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441 Publisher Name : Global Markets Direct Date: 22-Jul-2015 No. of pages: 54 Single User License: US $2000
  • 2. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Polycystic Ovarian Syndrome - Pipeline Review, H2 2015 © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
  • 3. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441 Polycystic Ovarian Syndrome - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research : Addex Therapeutics Ltd, AstraZeneca Plc, BIOCAD, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Merck KGaA and Vicore Pharma AB Drugs Profile Discussed in this Research : AZD-4901, C-21, choriogonadotropin alfa, ESN-364, follitropin alfa, JDSCR-004, KDT-501, metformin hydrochloride, Small Molecule to Antagonize FSH Receptor for Women's Health, Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome and Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology
  • 4. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441 Scope For Polycystic Ovarian Syndrome - Pipeline Review, H2 2015 • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics Polycystic Ovarian Syndrome - Pipeline Review, H2 2015
  • 5. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics Polycystic Ovarian Syndrome - Pipeline Review, H2 2015
  • 6. For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441 Polycystic Ovarian Syndrome - Pipeline Review, H2 2015

Related Documents